Results 141 to 150 of about 20,250 (180)

MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors. [PDF]

Neurooncol Adv
Kotch C, de Blank P, Fangusaro J, Fisher MJ.   +3 more
europepmc   +1 more source

Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review. [PDF]

Discov Oncol
Yang L, Liu X, Zhu X, Cao B, Gu Y, Liu W.   +5 more
europepmc   +1 more source

Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. [PDF]

Mol Cancer Ther
Houl JH, Bagheri-Yarmand R, Kunnimalaiyaan M, Miranda Mendez P, Kidd JL, Dadbin A, Ruiz-Jurado A, Parekh PA, Henderson YC, Chari NS, Thennavan A, Powell RT, Stephan CC, Zhao X, Maniakas A, Nurieva R, Busaidy NL, Cabanillas ME, Dadu R, Zafereo M, Wang JR, Lai SY, Hofmann MC.   +22 more
europepmc   +1 more source

Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer. [PDF]

Cell Rep
Devlin KL, Smith R, Bucher E, Dane M, Bowman CL, Carlson EJ, Kilburn D, Sudar D, Feiler HS, Heiser LM, Langer EM, Korkola JE.   +11 more
europepmc   +1 more source

Trametinib Decreased Intracerebral Hemorrhages and Endothelial-to-Mesenchymal Transition in KRAS^G12V-Induced Brain Arteriovenous Malformations in Mice. [PDF]

Stroke
Myint O, Freeman BH, Jeong J, Park H, Wilfur SM, Huang S, Park JE, Körbelin J, Aronowski J, Park ES, Chen PR, Kim E.   +11 more
europepmc   +1 more source

Positively Charged Polymers Based on Cyclodextrins for Trametinib and Selumetinib Delivery in Glioblastoma Cancer. [PDF]

ChemMedChem
Bognanni N, Gentile MT, Feola A, Giglio V, Dragone M, Isernia C, Vecchio G.   +6 more
europepmc   +1 more source

Ras-MAPK inhibition induces AXIN1 loss in colorectal cancer by mTOR associated suppression of protein synthesis. [PDF]

Cell Commun Signal
Venkatachalam N, Wang L, Muthukumarana N, Ihnatko R, Krijgsveld J, Skabkina O, Leipertz A, Chen Y, Sui P, Zheng Q, Tong P, Liu X, Descot A, Schewe M, Diamante G, Jackstadt R, Brochhausen C, Betge J, Boonekamp K, Boutros M, Stoecklin G, Ebert M, Schott J, Zhan T.   +23 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Trametinib

Reactions Weekly, 2023
  +8 more sources

Trametinib

Reactions Weekly, 2019
  +10 more sources

Trametinib (GSK1120212)

2018
The mitogen-activated protein kinase (MEK MAPK/ERK kinase) signaling pathways play a critical role in the regulation of diverse cellular activities, including survival, differentiation, proliferation, motility, and angiogenesis. Therefore, MEK inhibition was recognized as a promising target for antineoplastic therapy.
Zeiser, Robert, Andrlova, Hana, Meiss, Frank   +2 more
openaire   +3 more sources